Design and synthesis of a novel ZB716-d6 as a stable isotopically labeled internal standard

References

• https://en.wikipedia.org/wiki/ZB716.
   Google Scholar
• Liu, J.; Zheng, S.; Akerstrom, V. L.; Yuan, C.; Ma, Y.; Zhong, Q.; Zhang, C.; Zhang, Q.; Guo, S.; Ma, P.; et al. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD). J. Med. Chem. 2016, 59, 8134–8140.
   PubMed Web of Science ®Google Scholar
• Guo, S.; Zhang, C.; Bratton, M.; Mottamal, M.; Liu, J.; Ma, P.; Zheng, S.; Zhong, Q.; Yang, L.; Wiese, T. E.; et al. ZB716, a Steroidal Selective Estrogen Receptor Degrader (SERD), is Orally Efficacious in Blocking Tumor Growth in Mouse Xenograft Models. Oncotarget 2018, 9, 6924–6937.
   PubMedGoogle Scholar
• Zhang, C.; Guo, S.; Yang, L.; Liu, J.; Zheng, S.; Zhong, Q.; Zhang, Q.; Wang, G. Metabolism, Pharmacokinetics, and Bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD). Oncotarget 2017, 8, 103874–103889. DOI: https://doi.org/10.18632/oncotarget.21808.
   PubMedGoogle Scholar
• Pritchard, K. I.; Rolski, J.; Papai, Z.; Mauriac, L.; Cardoso, F.; Chang, J.; Panasci, L.; Ianuli, C.; Kahan, Z.; Fukase, K.; et al. Results of a Phase II Study Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer (FINDER2). Breast Cancer Res. Treat. 2010, 123, 453–461. DOI: https://doi.org/10.1007/s10549-010-1022-9.
   PubMed Web of Science ®Google Scholar
• Ohno, S.; Rai, Y.; Iwata, H.; Yamamoto, N.; Yoshida, M.; Iwase, H.; Masuda, N.; Nakamura, S.; Taniguchi, H.; Kamigaki, S.; Noguchi, S. Three Dose Regimens of Fulvestrant in Postmenopausal Japanese Women with Advanced Breast Cancer: results from a Double-Blind, Phase II Comparative Study (FINDER1). Ann. Onco. 2010, 21, 2342–2347. DOI: https://doi.org/10.1093/annonc/mdq249.
   PubMed Web of Science ®Google Scholar
• Robertson, J. F. R. Fulvestrant (Faslodex®)—How to Make a Good Drug Better. Oncologist. 2007, 12, 774–784. DOI: https://doi.org/10.1634/theoncologist.12-7-774.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT04669587.
   Google Scholar
• Stokvis, E.; Rosing, H.; Beijnen, J. H. Stable Isotopically Labeled Internal Standards in Quantitative Bioanalysis Using Liquid Chromatography/Mass Spectrometry: Necessity or Not? Rapid Commun. Mass Spectrom. 2005, 19, 401–407. DOI: https://doi.org/10.1002/rcm.1790.
   PubMed Web of Science ®Google Scholar
• Thienpont, L. M.; Van Uytfanghe, K.; Blincko, S.; Ramsay, C. S.; Xie, H.; Doss, R. C.; Keevil, B. G.; Owen, L. J.; Rockwood, A. L.; Kushnir, M. M.; et al. State-of-the-Art of Serum Testosterone Measurement by Isotope Dilution–Liquid Chromatography– Tandem Mass Spectrometry. Clin. Chem. 2008, 54, 1290–1297.
   PubMedGoogle Scholar
• Zhou, W.; Yang, S.; Wang, P. G. Matrix Effects and Application of Matrix Effect Factor. Bioanalysis 2017, 9, 1839–1844.
   PubMed Web of Science ®Google Scholar
• Van Eeckhaut, A.; Lanckmans, K.; Sarre, S.; Smolders, I.; Michotte, Y. Validation of Bioanalytical LC–MS/MS Assays: Evaluation of Matrix Effects. J. Chromatogr. B 2009, 877, 2198–2207. DOI: https://doi.org/10.1016/j.jchromb.2009.01.003.
   PubMed Web of Science ®Google Scholar
• Gant, T. G. Using Deuterium in Drug Discovery: Leaving the Label in the Drug. J. Med. Chem. 2014, 57, 3595–3611. DOI: https://doi.org/10.1021/jm4007998.
   PubMed Web of Science ®Google Scholar
• Pirali, T.; Serafini, M.; Cargnin, S.; Genazzani, A. A. Applications of Deuterium in Medicinal Chemistry. J. Med. Chem. 2019, 62, 5276–5297.
   PubMed Web of Science ®Google Scholar
• Traboulsi, T.; El Ezzy, M.; Gleason, J. L.; Mader, S. Antiestrogens: Structure-Activity Relationships and Use in Breast Cancer Treatment. J. Mol. Endocrinol. 2017, 58, R15–R31. DOI: https://doi.org/10.1530/JME-16-0024.
   PubMed Web of Science ®Google Scholar
• Liu, W.; Mo, L. Process for preparation of disulfide compound for synthesize of highly purified Fulvestrant. CN 104447447 B, 2017.
   Google Scholar
• Yuen, A. K. L.; Hutton, C. A. Deprotection of Pinacolyl Boronate Esters via Hydrolysis of Intermediate Potassium Trifluoroborates. Tetrahedron Lett. 2005, 46, 7899–7903. DOI: https://doi.org/10.1016/j.tetlet.2005.09.101.
   Google Scholar
• Gaboardi, M.; Manfrotto, C.; Di Giacomo, M. Process for the preparation of fulvestrant 3-boronic acid. WO 2020/187658 A1, 2020.
   Google Scholar
• Caprioglio, D.; Fletcher, S. P. An Alternative Synthesis of the Breast Cancer Drug Fulvestrant (Faslodex®): Catalyst Control over C–C Bond Formation. Chem. Commun. 2015, 51, 14866–14868. DOI: https://doi.org/10.1039/c5cc05805h.
   PubMedGoogle Scholar
• Du, L.; Li, M.; Zheng, S.; Wang, B. Rational Design of a Fluorescent Hydrogen Peroxide Probe Based on the Umbelliferone Fluorophore. Tetrahedron Lett. 2008, 49, 3045–3048.
   PubMed Web of Science ®Google Scholar